274 related articles for article (PubMed ID: 22352726)
21. Antidote-controlled platelet inhibition targeting von Willebrand factor with aptamers.
Oney S; Nimjee SM; Layzer J; Que-Gewirth N; Ginsburg D; Becker RC; Arepally G; Sullenger BA
Oligonucleotides; 2007; 17(3):265-74. PubMed ID: 17854267
[TBL] [Abstract][Full Text] [Related]
22. Aptamers as Therapeutic Agents: Has the Initial Euphoria Subsided?
Haßel SK; Mayer G
Mol Diagn Ther; 2019 Jun; 23(3):301-309. PubMed ID: 31037641
[TBL] [Abstract][Full Text] [Related]
23. Selection of an aptamer antidote to the anticoagulant drug bivalirudin.
Martin JA; Parekh P; Kim Y; Morey TE; Sefah K; Gravenstein N; Dennis DM; Tan W
PLoS One; 2013; 8(3):e57341. PubMed ID: 23483901
[TBL] [Abstract][Full Text] [Related]
24. Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.
Soule EE; Bompiani KM; Woodruff RS; Sullenger BA
Nucleic Acid Ther; 2016 Feb; 26(1):1-9. PubMed ID: 26584417
[TBL] [Abstract][Full Text] [Related]
25. A Highlight of Recent Advances in Aptamer Technology and Its Application.
Sun H; Zu Y
Molecules; 2015 Jun; 20(7):11959-80. PubMed ID: 26133761
[TBL] [Abstract][Full Text] [Related]
26. Aptamers: a new class of oligonucleotides in the drug discovery pipeline?
Dausse E; Da Rocha Gomes S; Toulmé JJ
Curr Opin Pharmacol; 2009 Oct; 9(5):602-7. PubMed ID: 19717337
[TBL] [Abstract][Full Text] [Related]
27. Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.
Rahimizadeh K; AlShamaileh H; Fratini M; Chakravarthy M; Stephen M; Shigdar S; Veedu RN
Molecules; 2017 Nov; 22(12):. PubMed ID: 29186905
[TBL] [Abstract][Full Text] [Related]
28. Nucleic acid therapeutics: a focus on the development of aptamers.
Jain S; Kaur J; Prasad S; Roy I
Expert Opin Drug Discov; 2021 Mar; 16(3):255-274. PubMed ID: 32990095
[TBL] [Abstract][Full Text] [Related]
29. Generation of an anticoagulant aptamer that targets factor V/Va and disrupts the FVa-membrane interaction in normal and COVID-19 patient samples.
Soule EE; Yu H; Olson L; Naqvi I; Kumar S; Krishnaswamy S; Sullenger BA
Cell Chem Biol; 2022 Feb; 29(2):215-225.e5. PubMed ID: 35114109
[TBL] [Abstract][Full Text] [Related]
30. Aptamers as Therapeutics.
Nimjee SM; White RR; Becker RC; Sullenger BA
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():61-79. PubMed ID: 28061688
[TBL] [Abstract][Full Text] [Related]
31. Regulation of thrombin activity with a bifunctional aptamer and hemin: development of a new anticoagulant and antidote pair.
Wang J; Cao Y; Chen G; Li G
Chembiochem; 2009 Sep; 10(13):2171-6. PubMed ID: 19650102
[No Abstract] [Full Text] [Related]
32. Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications.
Guan B; Zhang X
Int J Nanomedicine; 2020; 15():1059-1071. PubMed ID: 32110008
[TBL] [Abstract][Full Text] [Related]
33. Aptamers and SELEX in Chemistry & Biology.
Famulok M; Mayer G
Chem Biol; 2014 Sep; 21(9):1055-8. PubMed ID: 25237853
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic applications of synthetic nucleic acid aptamers.
Poolsup S; Kim CY
Curr Opin Biotechnol; 2017 Dec; 48():180-186. PubMed ID: 28582756
[TBL] [Abstract][Full Text] [Related]
35. Progress and Challenges in Developing Aptamer-Functionalized Targeted Drug Delivery Systems.
Jiang F; Liu B; Lu J; Li F; Li D; Liang C; Dang L; Liu J; He B; Badshah SA; Lu C; He X; Guo B; Zhang XB; Tan W; Lu A; Zhang G
Int J Mol Sci; 2015 Oct; 16(10):23784-822. PubMed ID: 26473828
[TBL] [Abstract][Full Text] [Related]
36. Emerging applications of aptamers for anticoagulation and hemostasis.
Chabata CV; Frederiksen JW; Sullenger BA; Gunaratne R
Curr Opin Hematol; 2018 Sep; 25(5):382-388. PubMed ID: 30015643
[TBL] [Abstract][Full Text] [Related]
37. Post-SELEX optimization of aptamers.
Gao S; Zheng X; Jiao B; Wang L
Anal Bioanal Chem; 2016 Jul; 408(17):4567-73. PubMed ID: 27173394
[TBL] [Abstract][Full Text] [Related]
38. Aptamers targeting cell surface proteins.
Takahashi M
Biochimie; 2018 Feb; 145():63-72. PubMed ID: 29198584
[TBL] [Abstract][Full Text] [Related]
39. Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties.
Hughes QW; Le BT; Gilmore G; Baker RI; Veedu RN
Molecules; 2017 Oct; 22(10):. PubMed ID: 29048375
[TBL] [Abstract][Full Text] [Related]
40. Advances in aptamers.
Syed MA; Pervaiz S
Oligonucleotides; 2010 Oct; 20(5):215-24. PubMed ID: 20677985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
